IBDEI04O ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,1502,2)
 ;;=^5049350
 ;;^UTILITY(U,$J,358.3,1503,0)
 ;;=T36.5X2S^^14^156^27
 ;;^UTILITY(U,$J,358.3,1503,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1503,1,3,0)
 ;;=3^Poisoning by aminoglycosides, intentional self-harm, sequela
 ;;^UTILITY(U,$J,358.3,1503,1,4,0)
 ;;=4^T36.5X2S
 ;;^UTILITY(U,$J,358.3,1503,2)
 ;;=^5049351
 ;;^UTILITY(U,$J,358.3,1504,0)
 ;;=T36.5X4A^^14^156^28
 ;;^UTILITY(U,$J,358.3,1504,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1504,1,3,0)
 ;;=3^Poisoning by aminoglycosides, undetermined, init encntr
 ;;^UTILITY(U,$J,358.3,1504,1,4,0)
 ;;=4^T36.5X4A
 ;;^UTILITY(U,$J,358.3,1504,2)
 ;;=^5049355
 ;;^UTILITY(U,$J,358.3,1505,0)
 ;;=T36.5X4D^^14^156^29
 ;;^UTILITY(U,$J,358.3,1505,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1505,1,3,0)
 ;;=3^Poisoning by aminoglycosides, undetermined, subs encntr
 ;;^UTILITY(U,$J,358.3,1505,1,4,0)
 ;;=4^T36.5X4D
 ;;^UTILITY(U,$J,358.3,1505,2)
 ;;=^5049356
 ;;^UTILITY(U,$J,358.3,1506,0)
 ;;=T36.5X4S^^14^156^30
 ;;^UTILITY(U,$J,358.3,1506,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1506,1,3,0)
 ;;=3^Poisoning by aminoglycosides, undetermined, sequela
 ;;^UTILITY(U,$J,358.3,1506,1,4,0)
 ;;=4^T36.5X4S
 ;;^UTILITY(U,$J,358.3,1506,2)
 ;;=^5049357
 ;;^UTILITY(U,$J,358.3,1507,0)
 ;;=T45.1X1A^^14^156^31
 ;;^UTILITY(U,$J,358.3,1507,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1507,1,3,0)
 ;;=3^Poisoning by antineopl and immunosup drugs, acc, init
 ;;^UTILITY(U,$J,358.3,1507,1,4,0)
 ;;=4^T45.1X1A
 ;;^UTILITY(U,$J,358.3,1507,2)
 ;;=^5051014
 ;;^UTILITY(U,$J,358.3,1508,0)
 ;;=T45.1X1D^^14^156^32
 ;;^UTILITY(U,$J,358.3,1508,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1508,1,3,0)
 ;;=3^Poisoning by antineopl and immunosup drugs, acc, subs
 ;;^UTILITY(U,$J,358.3,1508,1,4,0)
 ;;=4^T45.1X1D
 ;;^UTILITY(U,$J,358.3,1508,2)
 ;;=^5051015
 ;;^UTILITY(U,$J,358.3,1509,0)
 ;;=T45.1X1S^^14^156^33
 ;;^UTILITY(U,$J,358.3,1509,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1509,1,3,0)
 ;;=3^Poisoning by antineopl and immunosup drugs, acc, sequela
 ;;^UTILITY(U,$J,358.3,1509,1,4,0)
 ;;=4^T45.1X1S
 ;;^UTILITY(U,$J,358.3,1509,2)
 ;;=^5051016
 ;;^UTILITY(U,$J,358.3,1510,0)
 ;;=T45.1X3A^^14^156^34
 ;;^UTILITY(U,$J,358.3,1510,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1510,1,3,0)
 ;;=3^Poisoning by antineopl and immunosup drugs, assault, init
 ;;^UTILITY(U,$J,358.3,1510,1,4,0)
 ;;=4^T45.1X3A
 ;;^UTILITY(U,$J,358.3,1510,2)
 ;;=^5051020
 ;;^UTILITY(U,$J,358.3,1511,0)
 ;;=T45.1X3D^^14^156^35
 ;;^UTILITY(U,$J,358.3,1511,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1511,1,3,0)
 ;;=3^Poisoning by antineopl and immunosup drugs, assault, subs
 ;;^UTILITY(U,$J,358.3,1511,1,4,0)
 ;;=4^T45.1X3D
 ;;^UTILITY(U,$J,358.3,1511,2)
 ;;=^5051021
 ;;^UTILITY(U,$J,358.3,1512,0)
 ;;=T45.1X3S^^14^156^36
 ;;^UTILITY(U,$J,358.3,1512,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1512,1,3,0)
 ;;=3^Poisoning by antineopl and immunosup drugs, assault, sequela
 ;;^UTILITY(U,$J,358.3,1512,1,4,0)
 ;;=4^T45.1X3S
 ;;^UTILITY(U,$J,358.3,1512,2)
 ;;=^5051022
 ;;^UTILITY(U,$J,358.3,1513,0)
 ;;=T45.1X2A^^14^156^37
 ;;^UTILITY(U,$J,358.3,1513,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1513,1,3,0)
 ;;=3^Poisoning by antineopl and immunosup drugs, self-harm, init
 ;;^UTILITY(U,$J,358.3,1513,1,4,0)
 ;;=4^T45.1X2A
 ;;^UTILITY(U,$J,358.3,1513,2)
 ;;=^5051017
 ;;^UTILITY(U,$J,358.3,1514,0)
 ;;=T45.1X2D^^14^156^38
 ;;^UTILITY(U,$J,358.3,1514,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1514,1,3,0)
 ;;=3^Poisoning by antineopl and immunosup drugs, self-harm, subs
 ;;^UTILITY(U,$J,358.3,1514,1,4,0)
 ;;=4^T45.1X2D
